title: Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.
abstract: Recent efforts directed at potential litigation in Hawai'i have resulted in a renewed interest for genetic screening for cytochrome P450 2C19 (CYP2C19) polymorphisms in patients treated with clopidogrel. Clopidogrel is an antiplatelet agent, frequently used in combination with aspirin, for the prevention of thrombotic complications with acute coronary syndrome and in patients undergoing percutaneous coronary interventions. Cytochrome P-450 (CYP) 2C19 is an enzyme involved in the bioactivation of clopidogrel from a pro-drug to an active inhibitor of platelet action. Patients of Asian and Pacific Island background have been reported to have an increase in CYP2C19 polymorphisms associated with loss-of-function of this enzyme when compared to other ethnicities. This has created an interest in genetic testing for CYP2C19 polymorphisms in Hawai'i. Based upon our review of the current literature, we do not feel that there is support for the routine screening for CYP2C19 polymorphisms in patients being treated with clopidogrel; furthermore, the results of genetic testing may not be helpful in guiding therapeutic decisions. We recommend that decisions on the type of antiplatelet treatment be made based upon clinical evidence of potential differential outcomes associated with the use of these agents rather than on the basis of genetic testing.
authors: The Queen's Medical Center, Honolulu, HI.
authors: Adnan M
authors: AM
authors: Bhopalwala
authors: The Queen's Medical Center, Honolulu, HI.
authors: Robert A
authors: RA
authors: Hong
authors: The Queen's Medical Center, Honolulu, HI.
authors: Zia R
authors: ZR
authors: Khan
authors: The Queen's Medical Center, Honolulu, HI.
authors: Mona R
authors: MR
authors: Valentin
authors: The Queen's Medical Center, Honolulu, HI.
authors: Ramy A
authors: RA
authors: Badawi
mesh_terms: D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D006254:Hawaii; D006801:Humans; D008403:Mass Screening; D011110:Polymorphism, Genetic; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine
references: JAMA. 2011 Dec 28;306(24):2727-8
references: 22203545
references: Lancet. 1996 Nov 16;348(9038):1329-39
references: 8918275
references: Circulation. 2004 Jun 29;109(25):3171-5
references: 15184279
references: Lancet. 2009 Jan 24;373(9660):309-17
references: 19108880
references: Thromb Haemost. 2010 Apr;103(4):841-8
references: 20135063
references: JAMA. 2009 Aug 26;302(8):849-57
references: 19706858
references: N Engl J Med. 2001 Aug 16;345(7):494-502
references: 11519503
references: Circulation. 2014 May 27;129(21):2136-43
references: 24718568
references: J Am Coll Cardiol. 2012 Jun 12;59(24):2159-64
references: 22520250
references: N Engl J Med. 2009 Jan 22;360(4):354-62
references: 19106084
references: Lancet. 2010 Oct 16;376(9749):1320-8
references: 20801498
references: J Intern Med. 2002 Sep;252(3):233-8
references: 12270003
references: J Am Coll Cardiol. 2010 Jul 20;56(4):321-41
references: 20633831
references: N Engl J Med. 2010 Oct 28;363(18):1704-14
references: 20979470
references: JAMA. 2010 Oct 27;304(16):1821-30
references: 20978260
references: Clin Pharmacol Ther. 2006 Jul;80(1):33-40
references: 16815315
references: Circulation. 2003 Jun 17;107(23):2908-13
references: 12796140
references: J Am Coll Cardiol. 2012 May 29;59(22):1928-37
references: 22624833
references: J Clin Pharmacol. 2010 Aug;50(8):929-40
references: 20173083
references: J Pers Med. 2012 Oct 30;2(4):201-16
references: 25562360
references: Circulation. 2009 May 19;119(19):2553-60
references: 19414633
references: Pharmacogenomics J. 2011 Jun;11(3):199-206
references: 20351750
references: N Engl J Med. 2007 Nov 15;357(20):2001-15
references: 17982182
references: JACC Cardiovasc Interv. 2011 Apr;4(4):392-402
references: 21511218